Vireo Growth Inc. and Verano Holdings Corp. Announce Resolution of Litigation Matters

(CNSX:VREO),(OTC US:VREOF),(Other OTC:VREOF),(CNSX:VREO.CN),(Other OTC:VRNOF),(Neo:VRNO),(Neo:VRNO.NE), CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) today announced that they have reached a comprehensive settlement (the “Settlement Agreement”) dismissing all outstanding litigation matters between […]

Watsco Reports Record Third Quarter Gross Profit, Gross Margin and Operating Cash Flow in Challenging Market Conditions

(NYSE:WSO), MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced its operating results for the third quarter and nine-month period ended September 30, 2025. The Company also provided updates related to innovation and technology, business trends and long-term growth opportunities. Watsco is the largest distributor in the highly-fragmented $74 billion North American

OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th

(NASDAQ:OSUR), BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's

Amerigo Announces Q3-2025 Results, Full Debt Repayment and Quarterly Dividend Increase

(TSX:ARG),(OTC US:ARREF),(Other OTC:ARREF), Q3-2025 Net Income of $6.7 million, EBITDA1 of $18.7 million and Free Cash Flow to Equity1 of $11.1 million Full Debt Repayment Achieved in October 2025 Quarterly dividend Increased by 33% Quarterly Dividend of Cdn$0.04 Declared VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF)

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

(NASDAQ:AVXL), ADAS-Cog13 difference âˆ'12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI Restoring impaired Autophagy âˆ' preceding amyloid-beta and tau NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”)

Blue Gold Limited Sets Bold New Strategy as a Market Pioneering Vertically Integrated ‘Mine-to-Wallet’ Digital Gold Company

(NasdaqGM:BGL),(NasdaqGM:BGLWW), NEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) — Blue Gold Limited (Nasdaq: BGL) (“Blue Gold” or the “Company”), a next-generation gold development and technology company, sets out its vision, mission and strategy to become a market leading vertically integrated gold company. Blue Gold will seamlessly blend physical gold with digital innovation by tokenizing

GXO Announces Organizational Changes to Accelerate Growth

(NYSE:GXO), Appoints new leader of Americas & Asia Pacific; Simplifies management structure; Strengthens Execution GREENWICH, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world's largest pure-play contract logistics provider, today announced organizational changes to accelerate growth, simplify its structure, and strengthen execution. GXO CEO Patrick Kelleher said, “In my first

Southern Michigan Bancorp, Inc. Announces Third Quarter 2025 Earnings

(PinkSheets:SOMC),(Pinksheets:SOMC), COLDWATER, Mich., Oct. 29, 2025 (GLOBE NEWSWIRE) — Southern Michigan Bancorp, Inc. (OTC Pink: SOMC) announced third quarter 2025 net income of $3,019,000, or $0.65 per share, an increase of $433,000, or 16.70%, compared to net income of $2,586,000, or $0.57 per share, for the third quarter of 2024. For the first nine months

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

(NASDAQ:ACRS), WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris' Chief Executive Officer Dr.

Stock Yards Bancorp Reports Record Third Quarter Earnings of $36.2 Million or $1.23 Per Diluted Share

(NASDAQ:SYBT), LOUISVILLE, Ky., Oct. 29, 2025 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today reported record earnings of $36.2 million, or $1.23 per diluted

Scroll to Top